Orthomolecular medicine

1. Introduction

Version followed: Linus Pauling's definition of "orthomolecular psychiatry" (1968) and the megavitamin programme for schizophrenia associated with Abram Hoffer and Humphry Osmond, as described in the American Psychiatric Association's 1973 Task Force Report 7; current organisations are described only as far as sources confirm. The psychotherapist works alongside this method and does not practise, sell, prescribe or recommend orthomolecular treatment. Sections 1–3 describe the method as its proponents present it; section 4 is the psychotherapist's own work with a client who uses or is considering it.

What it is, as proponents describe it. Orthomolecular medicine is a nutritional approach built on the idea that health depends on the body's chemistry running correctly and that illness, including mental illness, can be prevented or treated by providing the "right" concentrations of substances normally present in the body, chiefly vitamins, minerals and other nutrients, often at amounts far above ordinary dietary intake. Pauling coined "orthomolecular"; the National Library of Medicine's Pauling exhibit glosses it as "the right molecules in the right amounts" and states that he first used the term in print in 1967 in relation to psychiatric therapy. His widely cited 1968 article on orthomolecular psychiatry held that mental health is "deeply correlated with an optimum molecular environment for the mind" and that mental disease is best treated by striving to achieve optimum concentrations of such substances. [source: NLM "Promoting Vitamin C"; Oregon State University Pauling chronology 1968–69; OSU "Later Years" curriculum page] Pauling's 1966 research notes speak of providing an "optimal molecular environment of the mind". [source: OSU "Later Years"]

Core idea of change (proponents' model). Psychiatric symptoms are attributed to biochemical imbalance or a nutrient dependency; correcting that chemistry with high-dose vitamins (in the founding psychiatric programme, mainly nicotinic acid or nicotinamide, with vitamin C, vitamin B6 and other B vitamins), dietary change and, where proponents judged it necessary, conventional psychiatric drugs and ECT, is held to restore health. [source: APA Task Force Report 7, 1973] The theory rests on the adrenochrome/methylation hypotheses of schizophrenia; the 1973 APA task force found that this rationale "has little scientific support". [source: APA 1973]

Who practises it. Historically psychiatrists and physicians (Hoffer and Osmond in Canada; Pauling as a chemist-advocate who co-founded an Institute of Orthomolecular Medicine in Palo Alto in 1973 with Arthur Robinson). [source: NLM; APA 1973] Today it is offered by some physicians, naturopaths, nutrition practitioners and supplement retailers under labels such as orthomolecular, megavitamin, nutritional or "biochemical" psychiatry. [synthesis] The International Society for Orthomolecular Medicine (ISOM) was founded in Vancouver in 1994 as an umbrella body for national orthomolecular societies, with Abram Hoffer as founding president; it reports member societies in more than 20 countries [source: ISOM, Who We Are; UIA profile]. Its president since June 2023 is Ilyes Baghli, succeeding Atsuo Yanagisawa [source: ISOM announcement, 1 June 2023]. Professional membership is open to regulated health providers (its list includes physicians, pharmacists, naturopathic doctors, psychotherapists and nutritionists) and gives access to online courses and continuing-education webinars, conference discounts and a practitioner directory listing; no certification or accreditation requirement is stated [source: ISOM, Professional Membership page].

Regulation and status (one line each).

• United States: vitamins and minerals are sold mainly as dietary supplements; "orthomolecular" is not a licensed profession and is practised within whatever licence the practitioner holds. [uncertain: not verified]
• Australia: vitamins are regulated as listed complementary medicines by the TGA, which requires warning labels on products containing vitamin B6 above a set amount because of peripheral neuropathy. [source: TGA safety alert]
• UK, Canada, EU: food-supplement and natural-health-product rules apply to the products; no specific licence for the practice. [uncertain: not verified]
• Regulatory status of the method: not a recognised medical specialty or approved treatment for any psychiatric or physical disease. [synthesis]
• Evidence status: the APA task force (1973) concluded that controlled attempts to replicate the megavitamin claims for schizophrenia had failed and that the HOD and "mauve factor" tests were unreliable for diagnosis. [source: APA 1973] Pauling's later high-dose vitamin claims, from colds to cancer, were judged by the medical community to go beyond the evidence. [source: NLM] No claim is made here that it treats cancer or any physical disease.

2. Framework

How the method is structured (as the 1973 report describes Hoffer's programme). Assessment included a psychological questionnaire (the HOD test) and, in some programmes, urine "mauve factor" testing. Phase I was mainly outpatient: vitamins plus dietary change (removing sugar and refined cereals, regular meals), with antidepressants or tranquillisers when needed, to be tapered slowly once well. Phase II added ECT for patients who were very depressed, very psychotic or not responding. Phase III covered chronic patients with further ECT and hospital care. Maintenance on vitamins and medication could be lifelong; if symptoms returned after a trial off medication, resuming medication and vitamins was advised. Later refinements added blood histamine, trace-element and mineral assessments. [source: APA 1973] Current practitioners' protocols vary and are [uncertain: not verified].

The psychotherapist's work alongside (this guide's framework). [synthesis] It runs inside ongoing therapy, not as a separate course.

• Phase A – Inquiry and record (first session where it arises; repeat at intake and reviews). Goal: a complete, non-judgemental picture of what the client takes, who advises them, what it costs and what they hope for. Move on when the client has described the regimen and its place in their life.
• Phase B – Meaning and explanatory model (can interleave). Goal: understand what draws the client (hope, control, distrust of psychiatry, identity, community, side-effect fears). Move on when the client can state their own goals and concerns.
• Phase C – Decision support and coordination (as needed). Goal: informed, values-based choices; with consent, the prescriber, psychiatrist or pharmacist knows what is being taken. Move on when coordination is in place or the client has declined it and that is recorded.
• Phase D – Monitoring and risk (every session while in use). Goal: early recognition of stopping prescribed medication, relapse signs, adverse-effect symptoms, restrictive eating and financial strain.
• Phase E – Review. Revisit at planned intervals and at any change (new practitioner, new products, pregnancy, plan to stop medication).

3. Guiding principles

[synthesis unless sourced]

• Curiosity before evaluation. Ask in a way that makes disclosure safe; the client who feels judged hides use.
• Never perform, sell, prescribe or recommend. Do not suggest, endorse, dose or source any vitamin, supplement or regimen, and do not advise starting, stopping or changing any medicine or supplement; route those questions to the prescriber or pharmacist.
• Attribute, don't adjudicate. Describe the method's ideas as its proponents hold them ("orthomolecular practitioners believe…") and give its evidence status plainly when asked, without ridicule.
• Autonomy with information. Adults may choose complementary approaches; your task is to ensure the choice is informed and free of coercion.
• Coordination is the safety net. The single most protective step is that the prescriber and pharmacist know everything taken, with the client's consent.
• Medication discontinuation is the main psychiatric risk. Treat any plan to stop antipsychotics, mood stabilisers or antidepressants in favour of supplements as a risk conversation to bring to the prescriber, not a lifestyle preference.
• "Natural" is not "harmless". High-dose vitamins have documented toxicity (e.g. liver injury with niacin and vitamin A; peripheral neuropathy with vitamin B6). [source: LiverTox; MSD Manual; TGA] Know the warning symptoms well enough to route, not to diagnose.
• Watch the plate as well as the pills. Dietary rules attached to the regimen can feed restrictive or orthorexic eating. [source: Academy of Nutrition and Dietetics]
• Children and pregnancy raise the threshold. Vitamin A excess in pregnancy can cause irreversible birth defects, and acute vitamin A poisoning is most often accidental ingestion by children. [source: MSD Manual]
• Separate your own commerce from care. No product sales, referral fees or course promotion to clients.
• Document. Record what the client reports taking, discussions held, consent to share and referrals made.

4. Intervention inventory

All interventions below are the psychotherapist's own work alongside orthomolecular treatment, not delivery of it. They are [synthesis] built on the risks and history in the cited sources; risk facts are cited where used. Cross-reference: health anxiety and somatic presentations, Domain II.

4.1 Routine, non-judgemental inquiry and recording

• Purpose / when: At intake, at reviews, and whenever the client mentions vitamins, supplements, "nutritional psychiatry", diet plans or a new practitioner. Clients often do not volunteer complementary use unless asked.
• Steps: (1) Ask an open, normalising question about anything taken for mood, sleep, energy or mental health, prescribed or not. (2) Ask who suggested it (practitioner, website, group, family). (3) Record product names and the practitioner type as the client reports them; do not judge or comment on amounts. (4) Ask whether the prescriber and pharmacist know. (5) Note costs and where products are bought. (6) Record in the notes as client report.
• Example language (illustrative): "Many people use vitamins or supplements alongside other care. Is there anything like that you're taking or thinking about, for your mood or anything else?" / "Who helped you put this together?"
• Watch for: Hesitation or defensiveness (signals expected judgement; slow down); vague answers about prescribed medication (may indicate it has been stopped); multiple practitioners; large or rising spend. Working: the client discloses freely and returns to the topic unprompted.

4.2 Exploring meaning, hopes and explanatory model

• Purpose / when: After disclosure, to understand why the approach matters to this client, which shapes every later decision.
• Steps: (1) Ask what the client understands is causing their difficulties. (2) Ask what they hope the regimen will change and by when. (3) Explore what draws them: control, a "natural" identity, mistrust after bad experiences with psychiatry, side-effect fears, family or community belief, a charismatic practitioner. (4) Reflect the underlying need (e.g. agency, fewer side effects) separately from the method. (5) Ask how they will know if it is or isn't helping.
• Example language (illustrative): "What's your own sense of what's going on in your body and mind?" / "It sounds like having something you can do yourself matters a lot after feeling sidelined by treatment before." / "What would tell you it's working, and what would tell you it isn't?"
• Watch for: Grievance with prior psychiatric care (validate the experience; it may be addressable with the prescriber); an all-or-nothing frame ("chemicals vs nature"); beliefs that could be psychotic content rather than a health choice (assess, see 4.7). Working: the client distinguishes their need from the product and names their own review criteria.

4.3 Information offered with permission

• Purpose / when: When the client asks your view or is weighing a significant change.
• Steps: (1) Ask permission before giving information. (2) Describe the method's claims in attributed terms. (3) Give its evidence status in a sentence (controlled trials of the founding niacin claims for schizophrenia did not replicate, per the 1973 APA task force). [source: APA 1973] (4) State that high-dose vitamins have known risks and that the prescriber or pharmacist is the right person to discuss specifics. (5) Check what the client heard.
• Example language (illustrative): "Would it help if I said what I know about how this approach has been studied?" / "Orthomolecular practitioners believe the right nutrient levels correct brain chemistry. When the original vitamin treatments for schizophrenia were tested in controlled trials, the results didn't hold up. That doesn't tell you what to do, but it's worth having."
• Watch for: Lecturing, ridicule or a rescuing tone; the client feeling cornered. Working: the client engages with the information and stays in conversation.

4.4 Values-based decision support

• Purpose / when: When the client is deciding whether to start, continue, combine or replace treatments.
• Steps: (1) Clarify the decision in the client's words. (2) Elicit their values (e.g. staying well enough to work, avoiding side effects, being in control). (3) Lay out options as the client and their clinicians describe them, including combining approaches under medical oversight. (4) Explore what each option risks for those values, including relapse. (5) Identify what information they still need and from whom (prescriber, pharmacist). (6) Agree a review point. No published orthomolecular-specific decision aid is cited here [uncertain: not verified]; use a generic values-clarification approach.
• Example language (illustrative): "If staying out of hospital is what matters most, how does each option sit with that?" / "What questions would you want answered by your psychiatrist before deciding?"
• Watch for: Pressure from you in either direction; decisions driven by a practitioner's urgency or sales. Working: the client makes a choice they can explain in terms of their own values.

4.5 Coordination with the prescriber, psychiatrist or pharmacist

• Purpose / when: Whenever the client takes high-dose supplements alongside prescribed medicines, plans changes, or has symptoms that might be adverse effects.
• Steps: (1) Explain why sharing matters (interactions, toxicity, relapse monitoring). (2) Obtain explicit, specific consent: who, what, for what purpose. (3) Encourage the client to bring the actual product list to the prescriber or pharmacist. (4) With consent, send a brief factual note: products reported, any plan to change medication, your observations. (5) Record consent, refusal and contacts. (6) If consent is refused and there is no imminent risk, respect it, revisit later and document.
• Example language (illustrative): "Would you be OK with me letting Dr [name] know what you're taking, so they can look at it alongside your prescription?" / "A pharmacist can check the whole list for overlaps; would you take it to them?"
• Watch for: Client asking you to keep the regimen secret from the psychiatrist (explore why; secrecy around medication change is a risk marker). Working: the prescriber is informed and the client experiences you as a bridge rather than a side.

4.6 Recognising possible adverse-effect symptoms and routing

• Purpose / when: In every session while high-dose vitamins are used. You are not diagnosing; you are noticing and routing.
• Steps: (1) Ask briefly about physical changes since the last session. (2) Know the warning features the sources give: for vitamin B6, tingling, burning or numbness, usually in hands or feet; risk rises when several B6-containing products are combined, and the vitamin may be labelled under chemical names (e.g. pyridoxine, pyridoxal 5-phosphate) [source: TGA]; for vitamin A, headache, drowsiness, nausea, dry rough skin, hair loss, joint pain, liver problems, raised intracranial pressure, and birth defects in pregnancy [source: MSD Manual]; for niacin, flushing, nausea and vomiting, and liver injury including rare acute liver failure, notably after formulation changes [source: APA 1973; LiverTox; Leung et al. 2018]. (3) If present, advise the client to contact their doctor or pharmacist promptly; urgent symptoms (confusion, jaundice, severe headache, vomiting) go to urgent medical care. (4) Document and, with consent, inform the prescriber.
• Example language (illustrative): "You mentioned tingling in your feet. That's something to get checked with your GP soon, and to tell them everything you're taking."
• Watch for: The client attributing symptoms to "detox" or "healing"; reluctance to see a doctor. Working: symptoms are medically assessed quickly.

4.7 Responding to plans to stop prescribed psychiatric medication

• Purpose / when: When a client (or family) plans or has started to stop antipsychotics, mood stabilisers or antidepressants in favour of supplements; this was a central feature of the founding megavitamin programmes, which included trials off medication. [source: APA 1973]
• Steps: (1) Ask non-judgementally what they have changed and when. (2) Do not advise on medication; say clearly that changes belong with the prescriber. (3) Explore the reasons (side effects, stigma, belief in cure) and validate the underlying concern. (4) Build or review an early-warning-signs and relapse plan (sleep loss, suspiciousness, withdrawal, elevated mood, hopelessness) with named contacts. (5) With consent, contact the prescriber promptly; if consent is withheld and risk is significant (re-emerging psychosis, mania, suicidality), follow your service's risk and confidentiality procedures. (6) Involve family or supporters where the client agrees.
• Example language (illustrative): "It makes sense that you want off something that's made you feel slowed down. Could we take that to Dr [name] so any change is done with them watching for early signs?" / "What were the first signs last time things got difficult?"
• Watch for: Early relapse signs; loss of insight; a practitioner advising abrupt cessation; suicidality. Working: medication decisions go through the prescriber and a relapse plan exists.

4.8 Eating-disorder and orthorexia awareness

• Purpose / when: When the regimen includes food rules (e.g. removing sugar or refined grains) or when the client describes an intensifying focus on "pure" eating.
• Steps: (1) Ask about eating, weight change and how flexible the food rules are. (2) Listen for warning signs the Academy of Nutrition and Dietetics lists (citing NEDA): compulsive label-checking, cutting out a growing number of foods or whole food groups, high distress when "healthy" food is unavailable, obsessive following of "healthy lifestyle" accounts, sudden avoidance of foods once enjoyed. [source: Academy of Nutrition and Dietetics] (3) Note that following a particular diet is not itself a disorder; concern arises with fixation, distress and impairment. (4) If signs are present, use your usual validated eating-disorder screening and refer for medical assessment and to a registered dietitian; severe restriction can lead to malnutrition and needs medical monitoring. (5) Give no food quantities or targets yourself.
• Example language (illustrative): "How do you feel if you can't stick to the food plan for a day?" / "It sounds like the list of safe foods has got shorter. Can we look at how that's affecting you?"
• Watch for: Weight loss, social withdrawal around meals, rigid rules justified as health; history of eating disorder. Working: flexibility returns or the client accepts dietetic and medical input.

4.9 Children, pregnancy and safeguarding

• Purpose / when: When a parent gives high-dose vitamins or orthomolecular regimens to a child, or the client is pregnant or planning pregnancy.
• Steps: (1) Ask what the child is given and whether the child's doctor knows. (2) Note that acute vitamin A poisoning is most often accidental ingestion by young children, that children are most affected by liver enlargement, and that infants can develop toxicity within weeks; high-dose vitamin A in pregnancy can cause irreversible birth defects. [source: MSD Manual] (3) Encourage the parent or pregnant client to discuss all supplements with the paediatrician, midwife or obstetrician; with consent, inform them. (4) Seek the child's assent and explain things in age-appropriate terms where the child is your client. (5) If a child is being given harmful amounts, shows signs of toxicity, is deprived of needed medical care or adequate nutrition, or prescribed treatment is withheld with risk of significant harm, follow local safeguarding procedures. (6) Store products out of reach is a general safety message any clinician may give. [synthesis]
• Example language (illustrative): "Does your son's doctor know about the vitamins? Some of them can build up in children, so it's worth checking together."
• Watch for: A child's symptoms reframed as "detox"; refusal of medical review; pregnancy with high-dose vitamin A products. Working: the child's or pregnancy care team is informed.

4.10 Financial strain, commercial pressure and conflicts of interest

• Purpose / when: When spending on tests, consultations and supplements is significant, or the client is recruited into selling.
• Steps: (1) Ask what the regimen costs per month and how that sits with their budget. (2) Ask about pressure to buy bundles, repeat proprietary tests, or recruit others (multi-level marketing). (3) Explore how decisions get made if a practitioner both diagnoses and sells. (4) Help the client set their own spending limit and review point. (5) Do not sell, recommend or take commission on any product or course yourself; declare any conflict of interest. Your profession's ethics code applies [synthesis; ethics code not verified here].
• Example language (illustrative): "Can we look at what this is costing you and whether that feels OK?" / "How do you feel when the practitioner suggests another test?"
• Watch for: Debt, secrecy from family, recruitment pressure, testimonials replacing evidence. Working: spending is within the client's own limit.

4.11 Group and practitioner influence

• Purpose / when: When the client belongs to an online or in-person community around orthomolecular or megavitamin treatment, or relies on one practitioner for all health decisions.
• Steps: (1) Ask how the community talks about psychiatry and people who take medication. (2) Explore what it would cost socially to question the regimen. (3) Map other sources of support. (4) Keep the client's own judgement central.
• Example language (illustrative): "What happens in the group when someone decides to go back on medication?"
• Watch for: Shunning of dissent, urging to cut off clinicians or family, fear-based messaging about medication. Working: the client can hold their own view within or outside the group.

4.12 Health anxiety and somatic presentations (cross-ref Domain II)

• Purpose / when: When repeated nutrient testing, supplement escalation and body-checking are driven by health worry or persistent somatic symptoms.
• Steps: (1) Map the cycle: symptom, worry, test or new supplement, brief relief, return of worry. (2) Use established CBT approaches for health anxiety and persistent physical symptoms (see Domain II): formulation, reducing reassurance seeking and checking, behavioural experiments, attention training. (3) Coordinate with the GP so medical review is planned rather than driven by anxiety.
• Example language (illustrative): "Each new test seems to help for a day or two, then the worry comes back. Shall we look at that pattern together?"
• Watch for: Escalating spending or products to soothe anxiety. Working: fewer checks and tests, more tolerance of uncertainty.

4.13 Supporting psychosis care alongside the treating team

• Purpose / when: When the client has schizophrenia or another psychosis, the condition for which megavitamin therapy was originally promoted. [source: APA 1973]
• Steps: (1) Keep evidence-based psychological work going (e.g. CBT for psychosis, family intervention) as your service provides it. [synthesis] (2) Hold regular liaison with the care coordinator or psychiatrist with consent. (3) Include supplement use and any plan for medication change in the relapse plan. (4) Support families who may be divided over orthomolecular approaches.
• Example language (illustrative): "Your mum feels strongly about the vitamins and your dad wants you to stick with the clinic. Can we find what you all agree on, like keeping you well and in college?"
• Watch for: Family conflict, loss of contact with the team. Working: the team stays involved and the client is stable.

4.14 Reporting routes

• Purpose / when: When a client suffers a suspected adverse effect, a product is misleadingly promoted, or a practitioner acts unsafely.
• Steps: (1) Encourage the client (or, with consent, the clinician) to report suspected adverse effects to the national medicines or supplement regulator; in Australia, the TGA encourages consumers and health professionals to report problems with medicines. [source: TGA] Equivalent routes in other countries (e.g. FDA MedWatch in the US, MHRA Yellow Card in the UK, Health Canada) [uncertain: not verified]. (2) Misleading health claims in advertising go to the advertising or consumer regulator. [synthesis] (3) Concerns about a registered practitioner go to their professional or licensing board. (4) Children at risk: safeguarding procedures (4.9).
• Example language (illustrative): "What happened to your nerves sounds like something the regulator collects reports on. Would you like help making a report?"
• Watch for: Fear of reprisal from the practitioner. Working: report made or decision recorded.

4.15 Documentation and review

• Purpose / when: Every session in which it is discussed.
• Steps: Record client-reported products, practitioners, consent to share, information given, risks noted, referrals and reports; set a review date and revisit at changes (pregnancy, new diagnosis, plan to stop medication).
• Example language (illustrative): "I'll note what we've talked about so we can come back to it in a month."
• Watch for: Notes that sound like endorsement or advice on amounts; avoid both. Working: a clear, neutral trail.

5. Handling problems

All guidance in this section is [synthesis] unless a source is shown.

• Client hides use or minimises it. Re-normalise, ask again at review, ask about specific product types rather than general "supplements"; avoid any reaction that sounds like disapproval.
• Client wants you to endorse or recommend products, amounts or a practitioner. Decline warmly and explain your role: "I can help you think it through and connect with your doctor, but I don't advise on vitamins or doses." Route to the prescriber or pharmacist.
• Client asks whether to stop medication. Do not answer yes or no; explore reasons, then bring it to the prescriber together (4.7).
• Strong anti-psychiatry stance or rupture after you raise risks. Name the rupture, acknowledge any real harms from past treatment, restate that the decision is theirs, and return to shared goals. Avoid debate about the theory.
• Stuck in all-or-nothing thinking. Explore intermediate options the client and their clinicians might discuss, such as combining approaches under medical oversight; use values work (4.4).
• Non-adherence to prescribed medication blamed on supplements. Explore without blame, involve the prescriber, update the relapse plan.
• Overwhelm from information and conflicting advice. Narrow to one decision at a time; identify one trusted medical contact.
• Symptoms explained away as "detox" or "adjustment". Name that symptoms need medical assessment regardless of their cause; escalate urgent signs (confusion, jaundice, severe headache, vomiting, numbness). [source for symptoms: TGA; MSD Manual; LiverTox]
• Emerging psychosis, mania or suicidality during a medication change. Follow standard risk assessment and crisis procedures; contact the treating team.
• Restrictive eating escalating. Screen, refer for medical and dietetic assessment; treat as an eating-disorder concern (4.8).
• Family conflict over the approach. Offer a family session focused on shared aims; keep neutral on the method, firm on safety.
• Practitioner is also the client's friend or community leader. Explore dual pressures; support the client's independent judgement.
• Your own reactions (frustration, rescuing). Use supervision; check you are not steering the client either toward or away from the method.

Harm account

What was actually done

• Origins and promotion. In the 1950s–60s Abram Hoffer and Humphry Osmond, psychiatrists in Canada (Saskatchewan [uncertain: not verified]), promoted high-dose nicotinic acid (niacin) for schizophrenia, grounded in the adrenochrome and methylation hypotheses. Early claims were strong, e.g. that nicotinic acid "greatly improves the outcome of schizophrenia". Pauling's 1968 article gave the approach the name "orthomolecular psychiatry". [source: APA 1973; OSU chronology]
• Assessment as patients experienced it. Patients completed the HOD (Hoffer–Osmond Diagnostic) questionnaire and in some programmes a urine "mauve factor" test; positive results were used to diagnose schizophrenia or a "subclinical" form. The task force found both tests unreliable and the HOD test "far from specific", so people with mania, depression or anxiety could be labelled schizophrenic. [source: APA 1973]
• Treatment course. Patients were warned to expect flushing, then started on large amounts of nicotinic acid or nicotinamide with vitamin C, B6 and other B vitamins, plus dietary rules (no sugar, no refined cereals, regular meals). Antidepressants and tranquillisers were added as needed and were to be tapered once the patient was well. Those who did not respond moved to a second phase with ECT, and chronic patients to a third phase with further ECT and hospital sessions. The task force noted Hoffer had at one time advocated ECT without anaesthesia, and that it was unknown whether this continued. Other additions it reported included penicillamine, high-dose thyroid hormone, high-dose antidepressants and butyrophenones. [source: APA 1973]
• Maintenance and trials off medication. Maintenance on vitamins and drugs could be lifelong; after years of wellness, a trial off medication was described as harmless, with return of fatigue, depression or anxiety taken as a signal to resume. [source: APA 1973]
• Publicity. The approach received extensive newspaper and magazine coverage; the task force described a public "broadside" in which Hoffer made claims about pregnancy without citing evidence and recommended self-treatment without physician supervision. [source: APA 1973]
• Official response. In July 1973 an APA task force chaired by Morris A. Lipton (with Thomas A. Ban, Francis J. Kane, Jerome Levine and Loren R. Mosher; consultant Richard Wittenborn) reviewed the evidence and found that "legitimate empirical attempts at scientific replication have failed". [source: APA 1973]
• Later extension. Pauling extended high-dose vitamin advocacy to colds and cancer; the medical community held these claims went beyond the evidence. [source: NLM]

How it caused harm

• Ineffective treatment in a serious illness. Controlled Canadian Mental Health Association studies found no therapeutic effect of nicotinic acid in schizophrenia, and in one study active-treatment groups "fared worse than the placebo group by all measures"; Wittenborn's study showed "a clear failure to replicate" general efficacy. [source: APA 1973] Time spent on an ineffective regimen is time without effective care. [synthesis]
• Misdiagnosis. Unreliable tests could label people with other conditions as schizophrenic, exposing them to the full programme and its stigma. [source: APA 1973]
• Direct toxicity. Reported adverse effects included flushing, nausea and vomiting, loss of appetite and hyperkeratosis (skin thickening); in one study five of fourteen patients stopped because of "severe and intractable adverse reactions" and were excluded from outcome figures. The task force concluded the claim of no toxicity was contradicted. [source: APA 1973] Niacin can cause liver injury at high doses, including rare acute liver failure; a published case described acute liver failure with brain dysfunction and clotting failure after switching from immediate-release to extended-release niacin. [source: LiverTox Vitamins; Leung et al. 2018] Vitamin A excess causes liver toxicity, raised intracranial pressure, bone fragility and irreversible birth defects in pregnancy, with children most affected. [source: MSD Manual] Vitamin B6 can cause peripheral neuropathy, even at low doses and especially when several products are combined; the TGA had received over 30 reports. [source: TGA]
• Medication discontinuation and relapse. Programmes framed trials off medication as harmless and encouraged self-treatment without physician supervision; for people with psychosis or bipolar disorder, stopping medication outside medical oversight risks relapse, hospitalisation and suicide. [source: APA 1973 for the practices; risk statement is synthesis]
• ECT without anaesthesia and polypharmacy within some programmes added physical and psychological risk. [source: APA 1973]
• Financial and relational harm. Ongoing supplements, tests and consultations cost money; family conflict arises when members disagree about medication. [synthesis]
• Most at risk: people with psychosis, bipolar disorder or severe depression; children; pregnant people; those with liver disease or eating disorders; those taking several overlapping supplements. [synthesis from sources above]

Recognising it today

• Names and rebrandings: "orthomolecular psychiatry", "megavitamin therapy", "nutritional" or "biochemical" psychiatry, "nutrient therapy", "vitamin cure" for schizophrenia or depression. [synthesis] Not every nutrition-in-mental-health service is orthomolecular; mainstream clinicians may correct a measured deficiency or advise on a balanced diet under medical care.
• Phrases and rationales to notice: a single biochemical cause for all mental illness; "cerebral pellagra"; claims that vitamins cure schizophrenia; proprietary or unvalidated diagnostic questionnaires or urine tests; "your medication is the problem, nutrients are the cure"; "flushing/symptoms mean it's working". [source for historical rationales: APA 1973; rest synthesis]
• Red flags in a practitioner or service: advising stopping or tapering psychiatric medication without the prescriber; discouraging contact with psychiatrists; diagnosing from unvalidated tests; selling the supplements they prescribe; escalating products when symptoms persist; claims of treating cancer or other physical disease; promoting self-treatment without medical supervision; testimonials in place of trials. [synthesis; self-treatment concern from APA 1973]
• How legitimate practice differs: nutrient treatment is targeted to a diagnosed deficiency, given under medical supervision, monitored, coordinated with the prescriber, and never replaces effective psychiatric treatment. [synthesis]

What to do instead and how to help those harmed

• Safer alternatives: evidence-based psychiatric care for psychosis, bipolar disorder and depression, with medication decisions through the prescriber; psychological therapies offered by services (e.g. CBT for psychosis, family intervention, CBT and other evidence-based therapies for depression and anxiety); dietary advice from a registered dietitian when nutrition is a concern. [synthesis]
• Assessment of affected clients: ask about past and current regimens, medication changes and relapses, physical symptoms (refer for medical assessment of liver, neurological or vitamin A-related symptoms), eating patterns, finances, and feelings about past choices or past psychiatric care.
• Therapeutic work: grief and regret over lost time or relapse; anger or shame toward practitioners or family; rebuilding trust with psychiatric services; family work where members took sides; support in relapse prevention.
• Children: where a child was given harmful products or denied needed care, follow safeguarding procedures and coordinate with the child's doctor (4.9).
• Ethical, reporting and legal duties: document; with consent, inform treating clinicians; report adverse effects to the national regulator (in Australia, the TGA) [source: TGA]; report misleading advertising to advertising or consumer regulators; raise concerns about registered practitioners with their licensing board; follow your profession's ethics code on avoiding harm and conflicts of interest [synthesis; uncertain: not verified]. Do not sell, recommend or dose any product yourself.

Sources

Web sources:

• [Megavitamin and Orthomolecular Therapy in Psychiatry: APA Task Force Report 7 (1973)](https://www.psychiatry.org/File Library/Psychiatrists/Directories/Library-and-Archive/task-force-reports/tfr1973_Megavitamin.pdf) (American Psychiatric Association; Lipton, chair; July 1973). Final conclusions/recommendations section [uncertain: not verified].
• Later Years: Molecular Disease and Orthomolecular Medicine (Oregon State University Special Collections, Linus Pauling Papers).
• The University of California, San Diego (1968–1969) (OSU Linus Pauling chronology).
• Promoting Vitamin C (US National Library of Medicine, Linus Pauling Papers exhibit).
• Vitamin A Toxicity (MSD Manual Professional Edition; L. E. Johnson; reviewed June 2026).
• Vitamins (LiverTox, NIDDK, NCBI Bookshelf; updated 2021).
• Niacin-Induced Anicteric Microvesicular Steatotic Acute Liver Failure (Leung K, Quezada M, Chen Z, Kanel G, Kaplowitz N. Hepatology Communications 2018;2(11):1293–1298).
• Health supplements containing vitamin B6 can cause peripheral neuropathy (Therapeutic Goods Administration, Australia).
• Orthorexia: An Obsession with Eating Pure (Academy of Nutrition and Dietetics; S. Klemm, 2021, reviewed 2026).
• Who We Are (International Society for Orthomolecular Medicine).
• ISOM Professional Membership (International Society for Orthomolecular Medicine).
• ISOM Announces Dr. Ilyes Baghli as New President (International Society for Orthomolecular Medicine; 1 June 2023).
• International Society for Orthomolecular Medicine (ISOM) (Union of International Associations, Yearbook of International Organizations profile).

Also cited: Pauling L. (1968). Orthomolecular psychiatry. Science [uncertain: volume and pages not verified]. Abram Hoffer exhibit, University of Saskatchewan Library [uncertain: not verified]. Professional ethics codes [uncertain: not verified].